Michael A. Metzger - Mar 4, 2025 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Mar 4, 2025
Transactions value $
-$61,303
Form type
4
Date filed
3/6/2025, 04:10 PM
Previous filing
Feb 12, 2025
Next filing
Mar 17, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $56.3K +7.81K +2.6% $7.20 308K Mar 4, 2025 Direct
transaction SNDX Common Stock Sale -$118K -7.81K -2.54% $15.05 300K Mar 4, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock options (Right to buy) Options Exercise $0 +7.81K $0.00 0 Mar 4, 2025 Common Stock 7.81K $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,321,245 options to purchase shares of common stock that are vested and immediately exercisable and a total of 805,428 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $15.00 to $15.27
F3 This option is fully vested.